OLDWICK, N.J.--(BUSINESS WIRE)--Mar 6, 2025--
AM Best has affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “aa-” (Superior) of the members of Metropolitan Life Insurance Group (collectively referred to as MetLife or the group). Concurrently, AM Best has affirmed the Long-Term ICR of “a-” (Excellent) and the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of MetLife, Inc. (headquartered in New York, NY) [NYSE: MET]. The outlook of these Credit Ratings (ratings) is stable. (See below for a detailed listing of companies and Long- and Short-Term IRs.)
The ratings reflect MetLife’s balance sheet strength, which AM Best assesses as strong, as well as its strong operating performance, very favorable business profile and appropriate enterprise risk management (ERM).
MetLife’s strong balance sheet strength assessment is supported by AM Best’s view of the consolidated holding company’s capital adequacy that is enhanced by the financial flexibility and the liquidity of its ultimate parent (MetLife, Inc.), which historically has maintained significant and steady levels of excess liquidity. Additionally, there has been a longer-term trend toward reduced liability risk on MetLife’s balance sheet, related to equity and interest rate risk as its product portfolio changes over time. MetLife’s financial leverage and interest coverage levels are at appropriate levels for the ratings. There are some risks with mortgage exposure and AM Best will continue to monitor the group’s exposure.
The group has a history of growing revenue and consistently positive operating performance metrics on a statutory and GAAP basis. Earnings are well-diversified by geography, business line and distribution channel. The group benefits segment has strong earnings and moderate growth with low earnings volatility. AM Best views the group’s operating performance as strong, with its focus on expanding its product offerings, concentration on higher margin product lines with steadier returns and lower expenses. AM Best views the group’s ERM as appropriate, as it continues to focus on improving its overall program, capital modeling and stress testing.
The ratings also reflect the group’s strong and defensible market positions in many of its core lines of business and the diversity in its product offerings and geographic markets in the United States, Asia and Latin America, as well as the Europe, Middle East and Africa regions.
The FSR of A+ (Superior) and the Long-Term ICRs of “aa-” (Superior) have been affirmed with stable outlooks for the following subsidiaries of MetLife, Inc.:
- Delaware American Life Insurance Company
- Metropolitan Life Insurance Company
- Metropolitan Tower Life Insurance Company
- SafeGuard Health Plans, Inc. (TX)
- SafeGuard Health Plans, Inc. (FL)
- SafeGuard Health Plans, Inc. (CA)
- MetLife Global Benefits, Ltd.
- Metropolitan General Insurance Company
The following Short-Term IRs have been affirmed:
MetLife Funding, Inc.—
- AMB-1+ (Strongest) on commercial paper
MetLife, Inc.—
- AMB-1 (Outstanding) on commercial paper
The following Long-Term IRs have been affirmed with a stable outlook:
MetLife, Inc.—
- “a-” (Excellent) on USD 500 million 3.60% senior unsecured notes, due 2025
- “a-” (Excellent) on USD 500 million 3.0% senior unsecured notes, due 2025
- “a-” (Excellent) on JPY 25.2 billion 0.495% senior unsecured notes, due 2026
- “a-” (Excellent) on JPY 64.9 billion 0.769% senior unsecured notes, due 2029
- “a” (Excellent) on JPY 7.1 billion 1.009% senior unsecured notes, due 2029
- “a-” (Excellent) on USD 1.0 billion 4.55% senior unsecured notes, due 2030
- “a-” (Excellent) on JPY 23.1 billion 1.415% senior unsecured notes, due 2031
- “a-” (Excellent) on JPY 10.7 billion 0.898% senior unsecured notes, due 2031
- “a-” (Excellent) on USD 600 million 6.50% senior unsecured notes, due 2032
- “a-” (Excellent) on USD 1.0 billion 5.375% senior unsecured notes, due 2033
- “a-” (Excellent) on JPY 16.7 billion 1.67% senior unsecured notes, due 2034
- “a-” (Excellent) on USD 750 million 6.375% senior unsecured notes, due 2034
- “a-” (Excellent) on JPY 26.5 billion 1.189% senior unsecured notes, due 2034
- “a-” (Excellent) on USD 750 million 5.3% senior unsecured notes, due 2034
- “a-” (Excellent) on USD 1.0 billion 5.70% senior unsecured notes, due 2035
- “a-” (Excellent) on JPY 24.4 billion 1.385% senior unsecured notes, due 2039
- “a-” (Excellent) on JPY 11.2 billion 1.953% senior unsecured notes, due 2039
- “a-” (Excellent) on USD 750 million 5.875% senior unsecured notes, due 2041
- “a-” (Excellent) on USD 750 million 4.125% senior unsecured notes, due 2042
- “a-” (Excellent) on USD 1.0 billion 4.875% senior unsecured notes, due 2043
- “a-” (Excellent) on JPY 15.5 billion 2.195% senior unsecured notes, due 2044
- “a-” (Excellent) on USD 500 million 4.721% senior unsecured debentures, due 2044
- “a-” (Excellent) on USD 1.0 billion 4.05% senior unsecured notes, due 2045
- “a-” (Excellent) on USD 750 million 4.6% senior unsecured notes, due 2046
- “a-” (Excellent) on USD 1 billion 5.0% senior unsecured notes, due 2052
- “a-” (Excellent) on USD 1 billion 5.25% senior unsecured notes, due 2054
- “a-” (Excellent) on JPY 23.5 billion 2.39% senior unsecured notes, due 2054
- “a-” (Excellent) on JPY 15.2 billion 2.448% senior unsecured notes, due 2059
- “bbb” (Good) on USD 1.25 billion 6.40% junior subordinated debentures, due 2066
- “bbb” (Good) on USD 500 million 10.75% junior subordinated debentures, due 2069
- “bbb” (Good) on USD 600 million floating rate non-cumulative preferred stock, Series A
- “bbb” (Good) on USD 500 million 5.875% non-cumulative preferred stock, Series D
- “bbb” (Good) on USD 805 million 5.625% non-cumulative preferred stock, Series E
- “bbb” (Good) on USD 1.0 billion 4.75% non-cumulative preferred stock, Series F
- “bbb” (Good) on USD 1.0 billion 3.85% non-cumulative preferred stock, Series G
MetLife Capital Trust IV—
- “bbb” (Good) on USD 700 million 7.875% exchangeable surplus trust securities (junior subordinated), due 2067
Metropolitan Life Insurance Company—
- “a” (Excellent) on USD 250 million 7.80% surplus notes, due 2025
Metropolitan Life Global Funding I— “aa-” (Superior) program rating
- “aa-” (Superior) on all outstanding notes issued under the program
The following indicative Long-Term IRs have been affirmed stable outlooks:
MetLife, Inc. —
- “a-” (Excellent) on senior unsecured debt
- “bbb+” (Good) on subordinated debt
- “bbb” (Good) on preferred stock
This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’sRecent Rating Activityweb page. For additional information regarding the use and limitations of Credit Rating opinions, please viewGuide to Best's Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please viewGuide to Proper Use of Best’s Ratings & Assessments.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visitwww.ambest.com.
Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250306040770/en/
CONTACT: Louis Silvers
Senior Financial Analyst
+1 908 882 2316
louis.silvers@ambest.com
Erik Miller
Director
+1 908 882 2120
erik.miller@ambest.com
Christopher Sharkey
Associate Director, Public Relations
+1 908 882 2310
christopher.sharkey@ambest.com
Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
erik.miller@ambest.com
KEYWORD: EUROPE UNITED STATES NORTH AMERICA NEW JERSEY
